IceCure Medical Ltd. (NASDAQ:ICCM) Given Consensus Rating of “Hold” by Analysts

Shares of IceCure Medical Ltd. (NASDAQ:ICCM) have earned an average recommendation of “Hold” from the five ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $62.70.

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Alliance Global Partners started coverage on IceCure Medical in a report on Monday, May 4th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a report on Tuesday, April 21st. Finally, Maxim Group decreased their price objective on IceCure Medical from $90.00 to $30.00 and set a “buy” rating for the company in a report on Thursday, May 14th.

IceCure Medical Stock Performance

Shares of NASDAQ:ICCM opened at $5.22 on Friday. The company has a fifty day moving average of $8.50 and a 200-day moving average of $15.56. The company has a market capitalization of $439.52 million, a PE ratio of -21.75 and a beta of 0.40. IceCure Medical has a 52-week low of $3.75 and a 52-week high of $42.00.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.90). The company had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.34 million. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%. On average, equities analysts forecast that IceCure Medical will post -0.15 EPS for the current fiscal year.

Institutional Trading of IceCure Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in IceCure Medical in the fourth quarter valued at $39,000. Concurrent Investment Advisors LLC acquired a new stake in IceCure Medical in the fourth quarter valued at $48,000. Finally, Jane Street Group LLC acquired a new stake in IceCure Medical in the fourth quarter valued at $67,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.